Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004–2023)

Figures & data

Figure 1. Overall situation. (A) Annual number of published articles; (B) Top five countries/regions with the highest number of publications; (C) Cluster analysis of inter-country cooperation relationships; (D) Chord diagrams of inter-State cooperation relations.

Figure 2. Analysis of author, institution, and journal. (A) Cluster diagram of inter-author collaborations; (B) Cluster diagram of inter-agency co-operation; (C) Annual publications in the top 5 journals in terms of number of publications; (D) Dual-image overlay of biologics-related journals in psoriasis.

Table 1. The top ten authors by number of publications.

Author	No.of Publications	No. of Local Citations	Total Link Strength	Country	Affilication
Feldman, Steven R	84	3165	2344	USA	Wake Forest University School of Medicine
Wu, Jashin J	60	953	1962	USA	University of Miami Miller School of Medicine
Megna, Matteo	57	798	3409	Italy	University of Naples Federico II
Gottlieb, Alice B	54	3299	2042	USA	cahn School of Medicine at Mount Sinai
Tsai, Tsen-Fang	50	805	1298	Taiwan, China	National Taiwan University Hospital
Armstrong, April W	49	2225	2172	USA	Keck School of Medicine, University of Southern California
Fabbrocini, Gabriella	49	717	2738	Italy	University of Naples Federico II
Menter, Alan	48	4676	2597	USA	Baylor Scott & White
Warren, Richard B	48	1491	2129	UK	Manchester NIHR Biomedical Research Center
Lebwohl, Mark	44	3783	2349	USA	Icahn School of Medicine at Mount Sinai

Figure 3. Analysis of reference. (A) Cluster analysis diagram for references; (B) Reference timeline chart; (C) Outbreak of cited references.

Table 2. The top five references with cited frequency.

Title	Journal	Citation count	Author	Year
Efficacy and safety of Guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial	J Am Acad Dermatol.	238	Blauvelt A	2017
Secukinumab in plaque psoriasis–results of two phase 3 trials	N Engl J Med.	234	Langley RG	2014
Efficacy and safety of Guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial	J Am Acad Dermatol.	203	Reich K	2017
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics	J Am Acad Dermatol.	191	Menter A	2019
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis	N Engl J Med.	178	Lebwohl M	2015

Table 3. The top five references with the centrality.

Title	Journal	Centrality	Author	Year
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial	J Am Acad Dermatol	0.24	Alan Menter	2008
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis	N Engl J Med	0.15	Christopher E M Griffiths	2010
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial	J Dermatol	0.13	Atsuyuki Igarashi	2012
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial	J Am Acad Dermatol	0.12	Alice B Gottlieb	2004
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial	Lancet	0.11	Alice Gottlieb	2009

Figure 4. Analysis of research hotspots. (A) Keyword co-occurrence chart; (B) Chart of temporal trends in research topics; (C) Keyword cluster analysis chart; (D) Keyword timeline chart.

Figure 5. Outbreak of keywords.

Data availability statement

All the results found during this study are available in this article.